# OnCo record preopanc-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/preopanc-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "preopanc-2" ;
  schema:name "PREOPANC-2"@en ;
  schema:alternateName "PREOPANC 2"@en ;
  schema:description "PREOPANC-2 asked whether the strongest chemotherapy given entirely before surgery beats the Dutch standard of gemcitabine chemoradiotherapy before and gemcitabine after; survival was the same, about 22 months in both arms, so both remain reasonable ways to treat first, and the question of surgery first against treatment first moves to Alliance A021806 and PREOPANC-3."@en ;
  schema:url <https://onco.cc/trials/preopanc-2/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(25)00363-8>, <https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002036-17> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/borderline-resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:institutions <https://onco.cc/institutions/erasmus-mc/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/chemoradiation/> ;
  onco:people <https://onco.cc/people/marc-besselink/> .